These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 8620669)
1. In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite. Machinist JM; Kukulka MJ; Bopp BA Clin Pharmacokinet; 1995; 29 Suppl 2():34-41. PubMed ID: 8620669 [TBL] [Abstract][Full Text] [Related]
2. Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography. Granneman GR; Braeckman RA; Erdman KA Clin Pharmacokinet; 1995; 29 Suppl 2():1-8. PubMed ID: 8620665 [TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers. Wong SL; Awni WM; Cavanaugh JH; el-Shourbagy T; Locke CS; Dubé LM Clin Pharmacokinet; 1995; 29 Suppl 2():9-21. PubMed ID: 8620676 [TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers. Awni WM; Braeckman RA; Cavanaugh JH; Locke CS; Linnen PJ; Granneman GR; Dubé LM Clin Pharmacokinet; 1995; 29 Suppl 2():112-24. PubMed ID: 8620667 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Awni WM; Hussein Z; Granneman GR; Patterson KJ; Dubé LM; Cavanaugh JH Clin Pharmacokinet; 1995; 29 Suppl 2():67-76. PubMed ID: 8620673 [TBL] [Abstract][Full Text] [Related]
8. The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton. Awni WM; Cavanaugh JH; Braeckman RA; Chu SY; Patterson KJ; Machinist JM; Granneman GR Clin Pharmacokinet; 1995; 29 Suppl 2():49-61. PubMed ID: 8620671 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. Awni WM; Braeckman RA; Granneman GR; Witt G; Dubé LM Clin Pharmacokinet; 1995; 29 Suppl 2():22-33. PubMed ID: 8620668 [TBL] [Abstract][Full Text] [Related]
10. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Machinist JM; Mayer MD; Shet MS; Ferrero JL; Rodrigues AD Drug Metab Dispos; 1995 Oct; 23(10):1163-74. PubMed ID: 8654206 [TBL] [Abstract][Full Text] [Related]
11. The effect of food on the pharmacokinetics of zileuton. Awni WM; Cavanaugh JH; Witt G; Granneman GR; Dubé LM Clin Pharmacokinet; 1995; 29 Suppl 2():62-6. PubMed ID: 8620672 [TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Awni WM; Cavanaugh JH; Leese P; Kasier J; Cao G; Locke CS; Dube LM Eur J Clin Pharmacol; 1997; 52(1):49-54. PubMed ID: 9143867 [TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of zileuton in healthy young and elderly volunteers. Braeckman RA; Granneman GR; Locke CS; Machinist JM; Cavannaugh JH; Awni WM Clin Pharmacokinet; 1995; 29 Suppl 2():42-8. PubMed ID: 8620670 [TBL] [Abstract][Full Text] [Related]
14. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Lu P; Schrag ML; Slaughter DE; Raab CE; Shou M; Rodrigues AD Drug Metab Dispos; 2003 Nov; 31(11):1352-60. PubMed ID: 14570767 [TBL] [Abstract][Full Text] [Related]
15. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine. Awni WM; Braeckman RA; Locke CS; Dubé LM; Granneman GR Clin Pharmacokinet; 1995; 29 Suppl 2():98-104. PubMed ID: 8620678 [TBL] [Abstract][Full Text] [Related]
16. Zileuton for asthma. Med Lett Drugs Ther; 1997 Feb; 39(995):18-9. PubMed ID: 9057778 [No Abstract] [Full Text] [Related]
17. Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography-tandem mass spectrometry. Pian P; Labovitz E; Hoffman K; Clavijo CF; Rzasa Lynn R; Galinkin JL; Vinks AA; Malik P; Christians U J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Oct; 937():79-83. PubMed ID: 24029553 [TBL] [Abstract][Full Text] [Related]
18. Drug interactions with zileuton. Lau R Lancet; 1997 May; 349(9063):1479-80. PubMed ID: 9164345 [No Abstract] [Full Text] [Related]